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Aneuploidy has been recognized as a hallmark of
cancer for more than 100 years, yet no general the-
ory to explain the recurring patterns of aneuploidy
in cancer has emerged. Here, we develop Tumor
Suppressor and Oncogene (TUSON) Explorer, a
computational method that analyzes the patterns
of mutational signatures in tumors and predicts
the likelihood that any individual gene functions
as a tumor suppressor (TSG) or oncogene (OG).
By analyzing >8,200 tumor-normal pairs, we pro-
vide statistical evidence suggesting that many
more genes possess cancer driver properties than
anticipated, forming a continuum of oncogenic
potential. Integrating our driver predictions with
information on somatic copy number alterations,
we find that the distribution and potency of TSGs
(STOP genes), OGs, and essential genes (GO
genes) on chromosomes can predict the complex
patterns of aneuploidy and copy number varia-
tion characteristic of cancer genomes. We pro-
pose that the cancer genome is shaped through
a process of cumulative haploinsufficiency and
triplosensitivity.
INTRODUCTION
A key goal of cancer research is to identify genes whose muta-
tion promotes the oncogenic state. Research over the last 40
years has identified numerous potent drivers of the cancer
phenotype (Meyerson et al., 2010; Stratton et al., 2009; Vogel-
stein et al., 2013). Perhaps the most striking characteristics of
cancer genomes are their frequent somatic copy number alter-
ations (SCNAs) and extensive aneuploidies. Deletions and ampli-
fications of whole chromosomes, chromosome arms, or focal
regions are rampant in cancer, as are other rearrangements948 Cell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc.such as translocations and chromothripsis. Understanding
how these events drive tumorigenesis is a major unmet need in
cancer research.
Though ostensibly random, these alterations follow a
nonrandom pattern that suggests that they are under selection
and are likely to be cancer drivers rather than passengers.
If so, we should be able to explain how they drive tumori-
genesis. A recent clue as to how this might work came from
the integration of a genome-wide RNAi proliferation screen
with focal SCNA information (Solimini et al., 2012). The screen
identified STOP and GO genes that are negative and positive
regulators of cell proliferation, respectively. Hemizygous
recurring focal deletions were enriched for STOP genes
and depleted of GO genes, suggesting that the deletions
maximize their protumorigenic phenotype through cumula-
tive haploinsufficiency of STOP and GO genes. Haploin-
sufficiency describes a genetic relationship in a diploid
organism in which loss of one copy of a gene causes a pheno-
type. The converse is triplosensitivity, in which an additional
copy of a gene produces a phenotype. However, the distribu-
tions of STOP and GO genes were not able to predict
aneuploidy or chromosome arm SCNA frequencies, perhaps
because they represent only one aspect of tumorigenesis
(proliferation) or are too diluted by nonhaploinsufficient genes.
We hypothesized that the drivers of sporadic tumorigenesis
might provide a more representative and potent set of STOP
and GO genes with which to explore this phenomenon.
Furthermore, this gene set may possess a higher frequency
of haploinsufficiency.
In this study, we developed methods to identify tumor sup-
pressor genes (TGSs) and oncogenes (OGs) from tumor DNA
sequences. We implicate many new drivers in cancer causation
and find many more cancer drivers than expected that exist in
a continuum of decreasing phenotypic potential. Furthermore,
we found that the distribution and potency of TSGs, OGs, and
essential genes on chromosomes can explain copy number
alterations of whole chromosomes and chromosome arms
during cancer evolution through a process of cumulative hap-
loinsufficiency and triplosensitivity.
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Figure 1. Prediction of TSGs and OGs
Based on Their Mutational Profile
(A) Schematic representation of ourmethod for the
detection of cancer driver genes based on the
assessment of the overall mutational profile of
each gene. The somatic mutations in each gene
from all tumor samples are combined and classi-
fied based on their predicted functional impact.
The main classes of mutations (silent, missense,
and LOF) are depicted.
(B) Schematic depicting the most important
features of the distributions of mutation types
expected for a typical TSG, OG, and neutral
gene. Compared to ‘‘neutral’’ genes, TSGs are
expected to display a higher number of in-
activating mutations relative to their background
mutation rate (benign mutations), and OGs are
expected to display a higher number of acti-
vating missense mutations and a characteristic
pattern of recurrent missense mutations in spe-
cific residues.
(C) A flowchart delineating the main steps in our
method for identifying TSGs and OGs, from the
classification of the mutations based on their
functional impact to the identification of the best
parameters through Lasso and their use for the
prediction of TSGs and OGs by TUSON Explorer
(or the Lasso method).
(D) Schematic related to (C) depicting the pa-
rameters selected by Lasso employed by TUSON
Explorer for the prediction of TSGs and OGs (HiFI, high functional impact). For TSGs, the parameters are the LOF/Benign ratio, the HiFI/Benign
ratio, and the Splicing/Benign ratio, whereas for OGs the parameters are the Entropy score and the HiFI/Benign ratio.
Also see Figure S1 and Table S1.RESULTS
Cancer driver genes have been described as mountains and hills
(Wood et al., 2007). Mountains are driver genes that are very
frequently mutated in cancer, whereas hills represent less
frequently mutated driver genes. It has become clear from recent
international sequencing efforts that most potent drivers (moun-
tains) have been discovered. A key issue is how to determine the
identity of the significant but less frequently mutated drivers, the
hills. A recent analysis searching for very high confidence cancer
drivers in a database of400,000mutations estimated that there
were 71 TSGs and 54OGs (Vogelstein et al., 2013). It is likely that
there also exist additional functionally significant cancer drivers
with weaker phenotypes and lower probabilities that are
selected less frequently. A central question is how to identify
these genes. In principle, with more samples analyzed, greater
statistical significance can be placed on the outliers, allowing
discovery of lower penetrance drivers. However, it is likely that
there is more information present in the current data that may
allow these lower frequency events to be detected.
To approach this question, we sought to devise a method to
predict TSGs and OGs in cancer based on the properties of
gene mutation signatures of these two distinct classes of driver
genes.We hypothesized that the proportion of the different types
of mutations with different functional impact would be informa-
tive in predicting these two types of drivers (Figure 1A). Each
gene has a background mutation rate that is dependent on tran-
scription, replication timing, and possibly other unknown param-eters, and this rate can be estimated by the number of mutations
that are unlikely to affect its function (such as silent or func-
tionally benign mutations), whose observed frequency is not
dependent on selective pressure during cancer evolution. The
proportion of functionally relevantmutations of particular classes
compared to this backgroundmutation rate will be dependent on
the degree of selection and will predict the likelihood that a gene
will act as a cancer driver. TSGs and OGs can be distinguished
among the cancer driver genes based on the characteristic
pattern of the different types of mutations (i.e., loss of function
[LOF], missense, silent) that are typically observed for those
two classes of drivers relative to neutral genes, as illustrated in
Figure 1B.
Identification of Parameters Predicting TSGs and OGs
We set out to determine the most reliable parameters for the
prediction of TSGs and OGs in an unbiased way (Figure 1C).
We used sequence data from >8,200 tumors from the COSMIC
(Forbes et al., 2010) and TCGA (http://cancergenome.nih.gov/)
databases and a recently published database (Alexandrov
et al., 2013) comprising >1,000,000 mutations (Figure S1 and
Table S1 available online). We defined a list of 22 parameters pri-
marily based on the different classes of mutations and used the
classification method Lasso and three training sets of known
TSGs and OGs (from the Cancer Gene Census, Futreal et al.,
2004) (Table S2A) and neutral genes to identify those parameters
that best predict the two classes of driver genes (see Experi-
mental Procedures). We employed PolyPhen2 to predict theCell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc. 949
functional impact of missensemutations in order to classify them
into those with potentially high (HiFI) or low (LoFI) functional
impact (Adzhubei et al., 2010). LoFI mutations are typically
conservative amino acid changes or changes in poorly
conserved residues. We defined the combination of silent and
LoFI missense as ‘‘Benign’’ mutations to provide a larger, more
reliable value for estimating background mutation rates. We
also defined the LOF mutations as the combination of nonsense
and frameshift mutations. As a majority of known OGs show an
atypical distribution of recurrent mutations in one or a few key
residues, we utilized entropy, a well-defined concept in physics
and information theory (Shannon andWeaver, 1949), to measure
the degree of reoccurring mutations within a gene. The Entropy
score represents the weighted sum of the probabilities, across
a gene, that a site is mutated (see Experimental Procedures).
The best parameters found by Lasso for the prediction of
TSGs andOGs are described below and are visualized in Figures
1D and 2.
Tumor Suppressors versus Neutral Genes
Themost predictive parameters for TSGs are: (1) the ratio of LOF
mutations to Benign (p = 2.51 3 1028, Wilcoxon, one-tailed
test); (2) the ratio of Splicing to Benign mutations (p = 4.6 3
1013); (3) the ratio of HiFI missense to Benign mutations (p =
3.2 3 1014); and (4) high-level deletion frequency (p = 1.46 3
108). A 20-fold cross-validation shows a high prediction accu-
racy of 93.2% on these training sets (Figure 2A and Table S2B).
Oncogenes versus Neutral Genes
The most predictive parameters for OGs are: (1) the entropy for
missense mutations (p = 2.2 3 1014); (2) the ratio of HiFI
missense mutations to Benign mutations (p = 1.2 3 109); and
(3) high-level amplification frequency (p = 1.4 3 106). The
20-fold cross-validation accuracy is 85.2% (Figure 2B and
Table S2B).
Tumor Suppressor Genes versus Oncogenes
One important aim of our prediction method is the discrimination
between TSGs and OGs. The most predictive parameters be-
tween these two sets are: (1) the ratio of LOF to Benignmutations
(p = 2.5 3 1016); (2) high-level amplification frequency (p =
1.3 3 109); (3) high-level deletion frequency (p = 7.6 3 106);
and (4) the ratio of Splicing to Benign mutations (p = 9.9 3
107). The 20-fold cross-validation accuracy is 91.9%. Overall,
Lasso identified parameters that make intuitive sense for these
classes of genes and clearly delineated TSGs and OGs from
each other and from neutral genes. In sum, we identified
independent parameters that strongly predict and distinguish
between TSGs and OGs (Figures 2C and 2D and Table S2B).
Identifying OGs and TSGs
Having identified the most predictive parameters, we developed
a method we call Tumor Suppressor and Oncogene Explorer
(TUSON Explorer) that combined selected parameters to derive
an overall significance and ranking for each gene as a potential
TSG or OG (Figure 1D). First, we derived a p value for each
gene for the ratios of LOF/Benign, Splicing/Benign, HiFI/Benign,
and Missense Entropy based on the comparison to the neutral
gene set (see Experimental Procedures). For the LOF/Benign
parameter, we applied a correction to normalize for the nonuni-
form codon usage among genes for the occurrence of nonsense950 Cell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc.mutations (see Experimental Procedures). Finally, we used an
extension of Liptak’s method to provide a combined p value
for the selected parameters for each gene. For TSGs, the com-
bined p values (and q values) were derived from individual values
from the LOF/Benign, Splicing/Benign, and HiFI/Benign param-
eters. For OGs, the combined values were derived from the
Missense Entropy and the HiFI/Benign parameters (Figure 1D).
The LOF/Benign parameter for discrimination between TSGs
and OGs was subsequently utilized to define a final list of OGs
and TSGs (see Experimental Procedures). TUSON Explorer
does not take into account SCNA information, and this allows
us to perform a rigorous analysis of our cancer driver genes for
their abilities to predict the frequency of deletion and amplifica-
tion (see below).
As a second strategy to predict the probability of a given gene
being a TSG or OG, we employed the Lasso model, which also
takes into account SCNAs (see Experimental Procedures). The
ranked lists of predicted TSGs and OGs by both Lasso and
TUSON Explorer are contained in Tables S3A and S3B. This
list provides a facile look-up table that can be easily sorted for
different parameters for all those who are interested in the muta-
tional behavior of a given gene in this data set.
Both ranking strategies performed similarly and eliminated the
problems of inappropriately including giant genes and genes in
highly mutable regions (Dees et al., 2012), without the need to
consider expression level or replication timing (Lawrence et al.,
2013). Importantly, both of our strategies distinguish between
TSGs and OGs, which are predicted to have functionally oppo-
site roles in the control of cell growth and have different implica-
tions for potential cancer therapeutics.
Estimates of the Numbers of TSGs and OGs
A ranking of this nature consists of truly significant genes mixed
with false-positive genes that obtain low p values by chance un-
der the null hypothesis. Thus, we sought to get an estimate of the
minimum number of TSGs and OGs by analyzing the distribution
of the combined p values for each class of cancer driver genes.
To achieve this, we utilized a histogram-based method (Mosig
et al., 2001) to estimate the number of rejected hypotheses
from the distributions of the combined p values calculated for
each gene. With our data set, this method estimated 320
TSGs and 250 OGs (Extended Experimental Procedures).
This long list of TSGs and OGs suggests that there are many
more drivers than anticipated and that they exist in a continuum
of decreasing potency (Discussion and Figure 7A). For the
analyses described below, we considered the top 300 TSGs
(q value < 0.18) and 250 OGs (q value < 0.22) as our working lists.
Given the fact that the deviation of the mutation signatures from
the normal pattern is a function of the degree of selection and the
frequency of mutation, increasing the number of tumor samples
will detect even more cancer drivers of progressively weaker
selective pressure. To determine the potential number of TSGs
upon additional sequencing, we applied TUSON and estimated
the number of TSGs (using Mosig’s method) on random subsets
of the data set with increasing numbers of samples and
observed that the number of predicted TSGs continues to
increase with additional samples. We observed that the rate of
increase in the predicted number of TSGs decreases slightly at
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Figure 2. Best Parameters Selected by Lasso for the Prediction of TSGs and OGs
(A–C) Box plot representations of the distribution of the values for the indicated parameters in the neutral genes (gray), TSG (red), and OG training set (green). The
median, first quartile, third quartile, and outliers in the distribution are shown. The p value for the difference between the two indicated distributions is shown as
derived by the Wilcoxon test.
(A) Box plots showing the distribution of LOF/Benign, HiFI missense/Benign, and Splicing/Benign ratios and the high-level frequency of focal deletion among the
neutral gene set and the TSG set.
(B) Box plots showing the distribution of Missense Entropy, HiFI missense/Benign, mean of PolyPhen2 score, and the high-level frequency of focal amplification
among the neutral gene set and the OG set.
(C) Box plots showing the distribution of LOF/Benign and Splicing/Benign ratios, high-level frequency of deletion and amplification among the TSG and OG sets.
(D) Plot of the LOF/Benign ratio and Missense Entropy for each gene, the best parameters for discriminating between TSGs and OGs. Specific genes with high
levels of LOF/Benign or Missense Entropy are shown along with their p values for being a TSG or an OG (TUSON Explorer).
Also see Figure S2 and Tables S2 and S3.the highest number of samples examined (Figure S2), indicating
a possible plateau at very large number of samples.
PAN-Cancer Mutational Analysis
Gene Ontology (GO) term and pathway analysis of our list of po-
tential TSGs showed enrichment for functions that are highlyrelevant to tumorigenesis, including cell-cycle control, embry-
onic development, promotion of differentiation, apoptosis, and
blood vessel development (Table S3C and Figure 3). In addition,
there was a strong enrichment for transcriptional regulation (q =
6.19 3 1011) and chromatin modification (q = 5.7 3 1012).
Furthermore, we noticed an enrichment for genes involved inCell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc. 951
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Figure 3. Representation of Predicted TSGs and OGs within Their Cellular Pathways
Placement of predicted cancer drivers within specific cellular pathways. TSGs and OGs were predicted by TUSON Explorer. The predicted TSGs and OGs
belonging to many known cellular pathways or complexes are shown, along with how they generally correspond to the hallmarks of cancer. TSGs are shown in
red, whereas OGs are shown in green; color intensity is proportional to the combined p value as indicated. For some pathways, additional genes absent from the
predicted TSGs andOGs were added andmarked in gray for clarity of the pathway representation. Although several genes are known to affect multiple pathways
and hallmarks, only one function is presented for the sake of limiting the complexity of the diagram. An external black box outside of the colored gene box
highlights genes previously less well characterized for their roles in tumorigenesis.
See also Figure S3 and Table S3.
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Figure 4. Representation of Mutation
Patterns in Representative Predicted TSGs
and OGs
(A–F) The mutational patterns of selected TSGs
and OGs are depicted. For TSGs (A–D), the loca-
tions of LOF (red) and silent (white) mutations
within the coding regions are shown. For OGs
(E and F), the location of recurrent missense mu-
tations (orange) and of LOF mutations (red) within
the coding regions are shown. USP28, TP53BP1,
and RASA1 are previously less well-characterized
candidate TSGs in the TUSON PAN-Cancer anal-
ysis. SPOP and PPP2R1A are previously less well-
characterized candidate OGs.
See also Table S3.the immune system (q = 5.8 3 103), particularly in antigen pro-
cessing and presentation represented by the MHC class I sys-
tem. Two major HLA genes (HLA-A and HLA-B) were in the top
90 candidate TSGs (q < 0.0002), and the b2 microglobulin
(B2M) gene, which is an obligatory complex component of
both HLA proteins, ranked 43rd (q = 9.2 3 109) on our TSG
list, underscoring that escaping from immunosurveillance is a
significant selective force in tumorigenesis (Hanahan and Wein-
berg, 2011) (Figures 3 and 4B). Furthermore, IL32, which stimu-
lates the immune responses of NK cells and CD8+ T cells that
monitor MHC status (Conti et al., 2007), is also in the top
50 TSGs. Unexpectedly, negative regulation of cell adhesion
(q = 4.32 3 104) was enriched, indicating that increase of cell
adhesionmay confer a selective advantage to tumor cells. Tradi-
tionally it has been thought that reducing adhesion promotes
tumorigenesis; however, recent findings suggest a potentially
different role for cell-to-cell-adhesion. First, it has been shown
that circulating tumor cells exist in clusters in the blood (Hou
et al., 2011). Second, PVRL4, which ranked well in our Lasso
OG list, was shown to promote transformation through cell adhe-
sion, as do several other oncogenes likeMYC, KRAS, PI3K, and
loss of PTEN (Pavlova et al., 2013). Thus, promotion of adhesion
may be a driving force in tumorigenesis.Cell 155, 948–962,New Potential Cancer Drivers
New components of pathways previously
linked to tumorigenesis have also been
detected (Figure 4). For example, the
DNA damage response pathway is cen-
tral to the maintenance of genomic
stability, and both members of a key
DDR complex, the TP53BP1/USP28
complex (Zhang et al., 2006), which are
substrates of the ATM kinase (Matsuoka
et al., 2007), were identified within the
top 110 TSGs (q < 0.15, Figures 3 and
4A–4C). Two components that regulate
ATM-dependent chromatin remodeling,
UBR5 and TRIP12 (Gudjonsson et al.,
2012), are also high on the TSG list (q <
0.25). RBMX, which controls ATR and
BRCA2 expression (Adamson et al.,
2012), ranked 76th on the list (q = 1.1 3104). There are several candidate OGswith enzymatic functions
that could serve as drug targets (Figure 4E and Tables S3B and
S7B), including three phosphatases (PPP6C, PTPN11, PTPRF)
and regulators such as PPP2R1A, as well as several kinases
(MAPK1, MAPK8, BRSK1 among others). There are many other
new potential TSGs and OGs on these lists that cannot be dis-
cussed here due to limitations of space, but several of these
are presented in Figure 3.
Consistent with the enrichment of cell-cycle and apoptosis GO
terms, integration of the PAN-Cancer analysis with functional
gene sets revealed that essential genes are significantly
depleted for deleterious mutations (see below). An exception
to that finding was the presence of RPL22, RPL5, and RPL18
large ribosomal subunit genes in the top 210 TSGs (q < 0.07;
Figure 3). Interestingly, heterozygous mutations in ribosomal
genes promote tumorigenesis in zebrafish (Lai et al., 2009).
Furthermore, familial mutations in ribosomal proteins have
been associated with Diamond-Blackfan anemia, which is asso-
ciated with an increased risk of leukemia (Willig et al., 2000).
Analysis of Individual Tumor Types
Identification of cancer drivers using the PAN-Cancer analysis
favors discovery of genes whose functions contribute to manyNovember 7, 2013 ª2013 Elsevier Inc. 953
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Figure 5. Behavior of Functional Gene Sets Relative to TSG Parameters
(A and B) Box plot representation of the distribution of the values for the indicated parameters in the neutral genes compared with the essential genes and STOP
genes. The median, first quartile, third quartile, and outliers in the distribution are shown. The p value for the difference between the two indicated distributions is
shown as derived by the Wilcoxon test.
(A) Box plots showing the distribution (orange) of LOF/Silent, Splicing/Benign, and HiFI missense/Benign ratios (gray) and the high-level frequency of focal
deletion among the neutral gene and STOP gene sets.
(B) Box plots showing the distribution of LOF/Silent, LOF/Kb, HiFI missense/Benign ratios and the high frequency of focal deletion among the neutral gene set
(gray) and the essential gene set (light blue).
See also Tables S3A, S5A, and S5B.different types of cancer. Certain cancer drivers may miss the
cutoff for significance in the PAN-Cancer analysis because
they are primarily involved in controlling tissue-specific differen-
tiation networks or because they are rate limiting for a particular
function in only certain tissues. Thus, we anticipate that new
drivers can be discovered through analysis of mutation signa-
tures in individual tumor types despite their lower numbers. We
performed the same analysis as above for each of 20 tumor
types (Tables S1, S4A, and S4B). This analysis found many
TSGs that are specific for one tissue type such as CDH1 and
GATA3 in breast adenocarcinoma, VHL and PBMR1 in kidney
clear renal cell carcinoma, and ID3 and NPM1 in hematological
malignances (Table S4A). Genes whose FDRs for the different
subtypes were below 0.25 were all already relatively highly
ranked in the PAN-Cancer analysis. This indicates that the ma-
jority of tissue-specific drivers were detected in the PAN-Cancer
analysis.
We wanted to determine how many new TSGs might be
expected from the analysis of a new cancer subtype. For this,
we calculated the number of TSGs in the whole data set lacking
an individual tumor type (Tables S4C) and compared this list to
the TSGs in that tumor type, which averaged 14 genes.We found
that the average new cancer type added about five TSGs to the
PAN-Cancer list. Thus, on average,70% of the TSGs detected
in a single tumor type were already detected in the PAN-Cancer
analysis performed after excluding the mutations in that type of
tumor. This suggests that most cancer genes selected during
tumor evolution act in cellular pathwayswhose role in tumorigen-
esis is widespread among different tumor types.954 Cell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc.Analysis of TSGs and OGs
Behavior of Functional Gene Sets
The PAN-Cancer mutation data set allows us to interrogate the
behavior of functional gene sets derived through experimental
approaches. We previously showed that STOP genes are over-
represented in regionsof deletion (Solimini et al., 2012). Examina-
tion of their abundance in the set of candidate TSGs showed that
STOP genes are significantly enriched in the TSG set (p = 0.0031,
Fisher’s exact test) comprising 10% of the top 300 TSGs (68%
more than expected). The STOP gene set showed a 50%
higher ratio LOF/Silent than the average for the neutral gene set
(p = 2.0 3 1018; Figure 5A). Furthermore, the STOP genes
showed a significant increase in the Splicing/Benign and HiFI/
Benign ratios, two of the most potent parameters for the predic-
tion of TSGs (Figure 5A). This analysis further underscores the
fundamental connection between cell proliferation and cancer.
We next investigated a high-confidence set of 145 genes
predicted to be essential at the cellular level based on their
housekeeping cellular functions and their high evolutionary
conservation (Table S5A and Experimental Procedures). This
set was depleted from regions of recurring deletions (Beroukhim
et al., 2010) by 43% (p = 0.0198, Fisher’s exact test), and a larger
set of 332 essential genes was depleted by 25% (p = 0.014).
Examination of the LOF/Silent ratio showed that, for the set of
145 genes, the frequency of LOF /silent was 27% lower than
the rate for the neutral gene set (p = 5.8 3 105; Figures 5B
and S5B). Additionally, the LOF/kb and HiFI/Benign ratios were
also significantly decreased in the essential gene set. Given
that the vast majority of the mutations and deletions in question
are heterozygous, the reduced LOF mutation and deletion fre-
quency of the essential genes as a group argues that between
25% and 45% are haploinsufficient. Interestingly, our TSGs
were enriched in recurring focal deletions (68%, p = 0.000281)
and were depleted from recurring amplifications (28%, p =
0.015), whereas the OGs were enriched in amplifications (25%,
p = 0.046) and depleted from focal deletions (23%), indicating
that amplifications are also likely to be Cancer Gene Islands.
General Properties of Cancer Drivers
High Interactivity
To search for unique properties of TSGs and OGs, we examined
the degree to which these drivers participate in protein com-
plexes using the CORUM database of experimentally validated
human protein complexes (Ruepp et al., 2010). We found that
both TSGs andOGswere significantly more likely to be in protein
complexes than a typical protein. The 13.4%of all proteins found
in CORUM are in a complex. However, 36.7% of the predicted
TSGswere in complexes (p = 3.13 1024), and 26.4%of the pre-
dicted OGs were in complexes (p = 3.5 108; Figure S3A).
High Betweenness
A second property of complexes is the degree to which they are
connected to other proteins and complexes. We explored this
by assessing a property called ‘‘betweenness,’’ which is propor-
tional to the number of times the protein is part of the shortest
paths between all pairs of proteins in a network. High between-
ness indicates a greater connectivity. The TSG and OG candi-
date gene lists were mapped onto the most current BioGRID
human protein-protein interaction network (Stark et al., 2006).
Both the predicted TSGs and OGs show a high degree of
betweenness (TSG p = 6.16 3 1032, OG p = 1.68 3 106; Fig-
ure S3B), indicating that they are optimally positioned to impact
information flow through networks.
Greater Length
Proteins with greater interactivity often have more domains.
Thus, we examined gene length. Cancer drivers are significantly
longer than the average gene (1,700 nt), with the mean for TSGs
at 3,234 nt (p = 23 1021) and OGs at 2,107 nt (p = 9.7 3 106).
Importantly, this observation is also characteristic of the genes in
our training sets (TSGs, 4,133 nt, p = 6.73 1010; OGs, 2,260 nt,
p = 0.0016).
An Unusually High Concentration of TSGs on the X
Chromosome
While examining the distribution of TSGs across chromosomes,
we found that the X is unusually enriched for TSGs (p = 0.0042,
exact binomial test) relative to autosomes. Examining the top
300 TSGs, we find that, although only 3.9% of all genes are on
the X, it contains 7.3% of all predicted TSGs (86%more than ex-
pected) and was the only chromosome with a significant enrich-
ment of TSGs (Table S5C). Given the fact that the X is functionally
haploid in both males and females, this observation has certain
implications for evolutionary selection of cancer drivers during
tumorigenesis and haploinsufficiency of TSGs (see Discussion).
Interestingly, in the top 400 TSGs, we found two potential
TSGs on the Y, ZFY and UTY (q < 0.22). Both have homologs
on the X that escape X inactivation, each of which also displays
tumor suppressor properties: ZFX (p = 0.019) and UTX/KDM6A(p = 3.3 3 1046). This could explain the observation that
frequent Y nullisomy is observed in prostate, renal cell, head
and neck, Barret’s esophageal adenocarcinoma, bladder,
pancreatic adenocarcinoma, and other cancers at frequencies
of 30%–80% (Bianchi, 2009; Kowalski et al., 2007).
Furthermore, we analyzed the silent mutation rates along
entire chromosomes and found an enhanced mutation rate
on the X chromosome relative to autosomes in males (30%
increase, p = 1.1 3 109). This increase is even greater in
females (77.5%, p = 1.63 1011) (Table S5D). Possible explana-
tions for this phenomenon are detailed in the discussion.
Distribution and Potency of Cancer Drivers on
Chromosomes Predict Arm and Chromosome SCNA
Frequencies
In addition to focal SCNAs, a less frequent but significant chro-
mosomal alteration is whole-arm loss or gain. We hypothesized
that the distribution and potency of TSGs and OGs on chromo-
somes might explain the average frequency of chromosomal
whole-arm SCNAs seen in cancer. To this end, we generated a
chromosome arm score, Charm, that provides an assessment
of each arm based on the density of TSGs and OGs and their
potency (weights of TSGs and OGs are based on their rank on
their respective lists and serve as a metric for their potency).
The Charm score represents ameasure of the amount of positive
or negative growth and survival potential that wild-type OGs or
TSGs might normally impart to a given arm and therefore how
SCNAs might impact cancer evolution by altering this balance
during tumorigenesis. Importantly, for Charm calculations, we
employed the parameters from TUSON Explorer, which does
not include copy number information. To lessen the diluting
impact of false positives for this analysis, we applied stringency
cutoffs of a q value of 0.25 for TSGs and 0.35 for OGs and a min-
imum of 10missensemutations for OGs and 8 LOFmutations for
TSGs to get a stringent list of 264 TSGs and 219 OGs (see Exper-
imental Procedures). The analysis of the CharmTSG score versus
frequency of chromosomal arm deletion revealed a strong posi-
tive correlation (r = 0.578, p = 5.8 3 105, Pearson correlation;
Figure 6A and Table S6A). Interestingly, the CharmTSG score
also showed a strong negative correlation with arm amplification
frequency, and thus a high CharmTSG score indicates a signifi-
cantly reduced tendency for a chromosome arm to be amplified
(r = 0.59, p = 2.8 3 105; Figure 6B). Simple TSG densities
without weighting by rank also showed correlations with arm
deletions (Figure S4A), but these correlations are improved by
Charm. In contrast to CharmTSG, the CharmOG score showed a
negative correlation with arm deletion frequency (r = 0.52, p =
3.2 3 104; Figure 6C). Moreover, the density of OGs positively
correlated with arm amplification frequency (r = 0.45, p = 1.8 3
103, Figure 6D) but was not improved by the Charm score
(data not shown).
We reasoned that, like GO genes in focal deletions, the chro-
mosome arms most frequently deleted in cancer would be
depleted of genes that promote the fitness of cancer cells. Using
our in silico list of essential genes, we estimated their fitness
potency by estimating their avoidance of damaging mutations
using the (LOF + HiFI)/Benign ratios. By determining a CharmEss
score for each arm, we found a negative correlation betweenCell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc. 955
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Figure 6. Charm Score, Chrom Score, and Copy Number Alterations: Correlation Analysis
(A–F) The Pearson’s correlation analysis of the Charm scores or Density score for the indicated gene sets (A–D) and/or combinations of these sets (E and F)
relative to the frequency of arm-level deletion or amplification. Ess, essential genes.
(G and H) The correlations of the Chrom scores (ChromTSG-OG-Ess and ChromTSG-OG) relative to the chromosome-level deletion or amplification frequency. The
Charm scores refer to a weighted density of TSGs, OGs, or essential genes present on each chromosome arm, where each TSG or OG is weighted based on its
rank position within the list of predicted TSGs and OGs ranked by TUSON Explorer and each essential gene is weighted based on its (LOF + 1/23 HiFI)/Benign
ratio. The Chrom score is the equivalent of the Charm score for whole chromosomes.
See also Figures 4 and 5 and Table S6.
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CharmEss scores and the frequency of arm-level deletions (r =
0.34, p = 1.6 3 102; Figure S4D). No correlation was found
between CharmEss and amplification frequency, as expected.
Because the CharmTSG, CharmOG, and CharmEss scores
correlate with arm-level deletion, we combined them by giving
a positive weight to the CharmTSG score and a negative weight
to the CharmOG and CharmEss scores to derive a cumula-
tive CharmTSG-OG-Ess score. The CharmTSG-OG-Ess score gave
an even stronger positive correlation with arm deletion fre-
quency (r = 0.77, p = 4.7 3 109; Figure 6E and Table S6A).
For amplification, we used the CharmTSG-OG score and found a
strong negative correlation with amplification frequency (r =
0.65, p = 3.63 106; Figure 6F). We also combined amplification
and deletion frequencies into a single score for copy number
variation on each arm and compared that to the CharmTSG-OG
score. This also gave a strong significant correlation (r = 0.74,
p = 2.7 3 108; Figure S5A).
We extended our analysis of cancer driver scores and SCNAs
to whole-chromosome aneuploidy using its Charm equivalent
score that we call Chrom (Figures 6G, 6H, S4E–S4H, S5B,
S5E, and S5F). ChromTSG significantly correlated with chromo-
some deletion frequency (r = 0.66, p = 3.7 3 104; Figure S4E)
and anticorrelated with amplification frequency (r = 0.54, p =
4.0 3 103; Figure S4F). Impressively, when we combined
all three classes—TSGs, OGs, and essential genes—the
ChromTSG-OG-Ess was strongly predictive of the frequency of
chromosome loss (r = 0.80, p = 3.2 3 106; Figure 6G), and
ChromTSG-OG was predictive of chromosome gains (r = 0.64,
p = 5.5 3 104; Figure 6H). Very similar results were obtained
using just the TUSON ranking without stringency cutoffs (Figures
S5C–S5F and Table S6B).
Together, these data strongly argue that a selective force in
generating chromosomal arm and whole-chromosome SCNAs
derives from the integration of the relative densities and
potencies of positively and negatively acting cancer drivers on
a particular chromosome. Thus, the SCNAs in cancer genomes
may be selected during tumor evolution through cumulative
haploinsufficiency for deletions (as previously proposed for
STOP genes in focal deletions [Solimini et al., 2012]) and through
cumulative triplosensitivity for amplifications (see Discussion).
DISCUSSION
In this study we analyzed the mutational data from >8,200 spo-
radic cancers to predict cancer driver genes. We determined
the most predictive parameters for identifying TSGs and OGs
and used them to develop an algorithm called TUSON Explorer
to predict the probability that an individual gene functions as a
TSG or an OG in cancer. This unbiased approach demonstrated
that the probability of being a cancer driver can be assessed by
the significance of the distortion of itsmutational pattern from the
pattern expected for a ‘‘neutral’’ gene. Combining data from our
analyses of drivers and copy number changes, the average
tumor in our data set has a mean number of 1 OG mutation,
3 TSG mutations (LOF and damaging missense), 3 chromo-
somal arm gains, 5 chromosomal arm losses, 2 whole-
chromosome gain, 2 whole-chromosome losses, 12 focal
deletions, and 11 focal amplifications (Zack et al., 2013).Thus, SCNAs comprise a very large proportion of cancer-driving
events.
A Continuum of Cancer Driver Genes
A central conclusion from this study is that there are likely to be
many more cancer drivers than anticipated. Our estimate of the
number of TSGs based either on the combined significance of
the different parameters or on the single best parameter for the
prediction of TSGs, i.e., the LOF/Benign ratio, predicted 320
TSGs with the current database from 8,200 tumors. Likewise,
we also predict more OGs than anticipated. The view of the can-
cer landscape emerging from our analysis does not contain a
clear cutoff for predicting cancer drivers. Instead, there exists
a continuum of decreasing probability of a given gene being a
driver (either TSG or OG). This probability is revealed by the
degree of selection that the gene experiences during tumor evo-
lution, which should be proportional to the phenotypic effect
caused by its loss or gain. This continuum of decreasing potency
of potential cancer drivers is likely to correspond to a continuum
of increasing numbers of genes with decreasing phenotypic
severity, as illustrated schematically in Figure 7A. In addition,
we hypothesize that events that simultaneously affect multiple
weak drivers can cumulatively have an effect equal to a single
potent driver. Our modeling of the progressively higher number
of driver genes identified as increasing numbers of tumors are
analyzed suggests that this number will continue to climb as
more sequence information becomes available but may be
beginning to plateau. However, the newly identified drivers are
likely to display progressively less potency with lower therapeu-
tic significance. This is analogous to GWAS studies for which
increasing sample sizes allow the identification of progressively
weaker acting variants.
Our analysis provides a probability of each gene being a can-
cer driver, and as such, there will be false positives regardless of
the threshold of minimum probability that we employ. Identifying
bona fide drivers from the regions with significant p values but
higher FDR values, i.e., weaker phenotypic signatures, can be
aided by considering other information such as their involvement
in SCNAs, biochemical connections to known OGs and
TSGs, and functional information gleaned from the literature.
These heuristic methods can be used to increase confidence
and rescue genes onto the likely cancer driver list (Tables S7A
and S7B).
PAN-Cancer and Tissue-Specific Analysis
Analysis of individual tumor types identified distinct sets of
drivers in each tumor type, but the majority of these were
also identified in the PAN-Cancer analysis as lower confidence
candidates (Tables S4A–S4C). Thus, although there is clearly
tissue specificity, there is still significant overlap among
different tumor types and a PAN-Cancer analysis samples a
sufficient number of similar tumors to detect most of the largely
tissue-specific or tissue-biased cancer drivers. Our analysis
suggests that significantly deeper sequencing of individual tu-
mor types is unlikely to uncover many new potent drivers
beyond what we have already identified and further sequencing
is likely to suffer from diminishing returns. This view is consis-
tent with a recent review that argues that nearly all potentCell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc. 957
A B
C D
Figure 7. Cumulative Haploinsufficiency and Triplosensitivity Shape the Cancer Genome
Illustrative schematics of different concepts highlighted in the Discussion.
(A) The phenotypic continuum of cancer drivers.
(B) The cancer gene island model for focal SCNAs.
(C) The cumulative gene dosage balance model for predicting the patterns of aneuploidy. (The panel depicts the concept for arm-level SCNAs.)
(D) Comparison of the predictions of Knudson’s Two-Hit Hypothesis for TSGs compared to the Haploinsufficiency Hypothesis presented in this study.drivers have been identified (Vogelstein et al., 2013).
Sequencing of more rare and relatively unexplored cancer
types may identify a few novel potent drivers that are specific
to those tumor types, but the vast majority of potent drivers
will already have been seen in other cancers. The major effects
of continued sequencing will likely be to solidify the continuum
by bringing much weaker drivers into the realm of statistical
significance.
Properties of New Potential Cancer Driver Genes
Analysis of the lists enriched for cancer drivers revealed several
general properties that distinguish them from nondriver genes.
The lists of both TSGs and OGs are strongly enriched both for
residence in protein complexes and for a property known as
betweenness, which is a measure of the degree to which a set
of genes is enriched for hubs within an interaction network.
Thus, the driver genes are much more highly connected
than the average protein in the human gene network and958 Cell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc.are longer. Highly connected nodes are better positioned to
control the flow of information, and their removal or hyperactiva-
tion will have the highest impact across a network due to their
centrality.
Unexpected Properties of the X Chromosome
Given the potentially deleterious effects of mutating TSGs, we
anticipated that TSGs would be depleted from the X chro-
mosome by natural selection, as the X is haploid in males and
is functionally haploid in females due to dosage compensation.
However, our analysis revealed just the opposite—namely, that
the X has 86% more TSGs than expected. Oncogenes, on the
other hand, are not overrepresented on the X. The likely explana-
tion is that a deleteriousmutation in a TSG on the X ismore pene-
trant because there is not a WT copy to compensate for its loss.
This further suggests that natural selection has not completely
depleted TSGs from the X, possibly because cancer is largely
a postreproductive disease.
We found a higher mutation rate for the X than for autosomes,
and this is further exaggerated in females. In females, the addi-
tional increase in X mutability is likely due to the presence of
the inactive X, which has very little transcription and, hence,
less transcription-coupled repair and is enriched in late-repli-
cating heterochromatin, which tends to be more mutagenic
(Stamatoyannopoulos et al., 2009). The mechanism underlying
these differences and their biological significance remains to
be determined. However, these differences might indicate that
the mutation rates of whole chromosomes are set by evolution
and that the higher mutability of the X is advantageous over
evolutionary time if it also occurs in the germline.
Haploinsufficiency and Cancer
The clonal expansion theory of tumorigenesis argues that, in
order for an individual mutation to be selected, it must cause
an expansion of the clone derived from that mutant cell by
increasing its relative proliferation and survival (Vogelstein and
Kinzler, 1993). This is intuitive for OGs, as they are dominant,
but it is less so for TSGs. For a hemizygous mutation in a TSG
to be selected in cancer, we have to assume that either the
mutation is dominant negative or the TSG is haploinsufficient.
Our current analysis of the degree to which essential genes are
absent from hemizygous recurring focal deletions, coupled
with the reduced frequency with which essential genes experi-
ence LOF mutations in tumors, conservatively suggests 30%
haploinsufficiency overall among human genes (Experimental
Procedures). A recent analysis of haploinsufficiency by the
mouse knockout consortium (White et al., 2013) found that
42% of genes examined produced a phenotype when heterozy-
gous, similar to our estimates. Evidence suggesting that our
sporadic TSG list is largely haploinsufficient comes from a com-
parison of the enrichment in focal deletions of STOP genes
versus our sporadic TSGs. STOP genes, which are TSG-like,
are enriched by 20% (Solimini et al., 2012). If we assume that
only 30% of this gene set is haploinsufficient and that all of
the selective enrichment comes from haploinsufficient genes,
then a list of purely haploinsufficient STOP genes would be
expected to be enriched by 67%. Perhaps coincidentally, our
list of TSGs is enriched 68% in recurring focal deletions, sug-
gesting that a significant proportion, and possibly all, of sporadic
TSGs are haploinsufficient.
We propose that two classes of TSGs might exist: those that
are haploinsufficient and contribute to sporadic cancer and
those that are haplosufficient and do not significantly contribute
to sporadic cancer through mutation. Circumstances under
which organisms inherit only one functional copy of those haplo-
sufficient TSGs might result in cancer because loss of the sec-
ond allele would produce a selectable phenotype. This situation
occurs with familial TSGs and the classic Two-Hit model of
tumorigenesis. Our hypothesis is consistent with the fact that,
out of a list of 73 familial TSGs culled from the literature, only
32% of them had a combined q value <0.25 in the PAN-Cancer
analysis (Table S3D). Another circumstance with only one func-
tional allele per cell occurs on the X, where we see a 86%
higher density of TSGs than on the autosomes. If the predicted
rate of 30% haploinsufficiency is correct, then one might
expect a 200% increase over autosomes, but negative selec-tive pressure on the X could have reduced that number. Thus,
it is possible that there are actually similar densities of TSGs
on the X and autosomes (haploinsufficient sporadic TSGs and
haplosufficient potential TSGs), but those on the X realize their
tumorigenic potential at a higher rate than do those on the
autosomes.
The PAN-Cancer Mutational Analysis Predicts
Aneuploidy in Cancer
Aneuploidy is a hallmark of cancer and can have both advanta-
geous and deleterious consequences for cells (Tang and
Amon, 2013; Luo et al., 2009), but there is no general theory
that explains how patterns of aneuploidy emerge. Knowing the
identity and potential potency of cancer drivers has allowed us
to uncover a driving force behind selection of arm- and chromo-
some-level SCNAs. Our analysis using Charm and Chrom as an
integrated assessment of the density and potency of the different
classes of cancer driver genes on chromosomes displayed a
robust ability to predict the patterns of whole-arm amplifications
and deletions and aneuploidy (Figures 6, S4, and S5). The fact
that the Charm score improves the correlations with SCNAs
compared to the simple gene density of the different classes of
genes indicates that the ranking of driver genes by TUSON
Explorer is likely to represent an accurate estimate of the
potency of their phenotypic effect in cancer and further supports
the continuum theory.
DensOG and CharmOG do not predict arm amplification as well
as CharmTSG. This reduced predictive potential is likely to be
because the OGs were selected on the basis of the ability to
be activated by mutation and because simply increasing the
dosage by 50% might not strongly impact the networks they
control. CharmOG, however, does show a strong negative corre-
lation with arm deletion frequency, indicating that, normally, the
WT OGs are acting to promote proliferation and survival and the
cumulative reduction of their levels by 50% is deleterious. In this
respect, the OGs are behaving like the essential genes, and the
inclusion of a high-confidence list of 332 essential genes
together with OGs and TSGs further improves the predictive abil-
ity for armdeletions (Figure 6E). As expected, the essential genes
have no predictive power for amplifications.
CharmTSG strongly predicts whole-arm deletions. Unexpect-
edly, it also strongly predicts arm amplification, providing a
strong negative correlation. This suggests that increasing the
gene dosage of a group of TSGs can have deleterious effects
on tumorigenesis through the process of cumulative triplosensi-
tivity. If TSGs are truly haploinsufficient, their WT protein levels
may be only marginally sufficient to execute their roles. If so,
TSGs may well be more sensitive to increased gene dosage to
further enhance their pathways than typical genes. In other
words, haploinsufficient genes may be more likely to display
triplosensitivity. This property of sporadic TSGs being both
haploinsufficient and triplosensitive, therefore, may make their
cumulative Charm score an even better parameter to explain
SCNAs of chromosome arms and aneuploidy in general. Devel-
oping a combined CharmTSG-OG-Ess and ChromTSG-OG-Ess score
can now predict 80% of the frequency of arm and chromo-
some loss and 65% of the amplifications observed across all
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Although the correlation between Charm/Chrom scores and
SCNAs is striking, there are several areas for improvement.
The first area concerns our lack of knowledge of the full comple-
ment of essential genes and which of these are haploinsufficient.
Second, only a subset of OGs will be dosage sensitive, and this
knowledge would improve the correlation. In addition, there are
two classes of OGs. Class I contains classical oncogenes such
as KRAS that are activated by mutation but whose WT copies
are not necessarily oncogenic after overexpression and will not
be predictive of amplification. Class II contains genes such as
cyclin D that can be activated by overexpression but are difficult
to activate by missense mutations and thus lack a mutational
signature. Class II OGs cannot be identified with confidence
through mutational signatures yet are likely to display triplosen-
sitivity and would positively correlate with amplification. Third,
some TSGs can be difficult to distinguish from OGs. These are
TGSs that have low haploinsufficiency but can produce a select-
able phenotype by generation of dominant-negative alleles.
Such genes will lack a strong LOF signature but will show a sig-
nificant number of deleterious missense mutations, which are
likely to predominantly occur in one or a few crucial residues,
thus conferring a significant Entropy score. In addition, early
SCNA events might influence subsequent events, as is the
case when specific aneuploidy co-occurs (Ozery-Flato et al.,
2011), which would confound our analysis to some degree.
Finally, refining these lists of cancer drivers will only improve their
predictive power. The current programs for prediction have their
strengths and weaknesses and are likely to be further improved
in the future. More precise knowledge of these essential and
cancer driver genes should significantly improve SCNA predict-
ability and our understanding of the cancer genome. Finally, the
SCNA frequencies might vary according to tumor type; thus,
comparison of data sets within one tumor type might provide
more predictive power. In addition, we do not know the back-
ground frequency of SCNAs upon which selection acts, so the
observed SCNA frequency cannot be normalized like mutation
rates can, and therefore, the observed SCNA frequency de-
tected might reflect both frequency of the event and its selective
power, which could confound the correlation.
Models of Cancer Evolution
Our work suggests a very important role for cumulative haploin-
sufficiency and triplosensitivity operating during cancer evolu-
tion to drive tumorigenesis. In each genomic region, there are
STOP (TSG) and GO (OG and essential) genes that will exert a
negative or positive phenotypic effect on tumorigenesis. Both
for focal deletions as illustrated by theCancer Gene IslandModel
(Figure 7B) and for chromosomes and chromosomal arm SCNAs
as indicated by the Charm and Chrom analysis (Figure 7C), the
integrated cumulative balance of these positive and negative
tumorigenic effects of individual genes affected in each SCNA
event provides the selective potency to that event and can pre-
dict its frequency across cancers.
For the past 40 years, the tumor suppressor field has been
guided by Knudson’s classical Two-Hit Hypothesis of tumori-
genesis for familial cancers. Though there are certainly bona
fide examples of the Two-Hit Model in sporadic cancer, this
model conflicts with the theory of clonal evolution of sporadic960 Cell 155, 948–962, November 7, 2013 ª2013 Elsevier Inc.cancer in the assumption that the first hit is fully recessive and
a second hit is required to contribute to tumorigenesis. While it
is difficult to measure the frequency with which the Two-Hit
Hypothesis operates in cancers because the role and extent of
methylation inactivation is not yet known in each tumor, analysis
of LOF mutational events suggests that it may be a relatively
infrequent event except in the case of a few genes such as
TP53 (p53) and CDKN2A (p16), both of which are inducible
responders to oncogenic stress, which can increase during
tumorigenesis. In the cases of sporadic cancer, wherein the
two-hit hypothesis does operate, it is still possible and even
probable that the genes involved are haploinsufficient to begin
with. Our results have led us to propose that the vast majority,
if not all, of sporadic TSGs are likely to be haploinsufficient and
that, therefore, sporadic TSGs are most likely to operate through
the Haploinsufficiency Model shown in Figure 7D. It is important
to note that these hypotheses are not mutually exclusive, as loss
of the second allele of a haploinsufficient TSG, the second hit,
will undoubtedly provide a stronger selective pressure than the
first hit. However, a tumor has multiple paths through which to
evolve, and it may not require loss of that second allele as it
obtains growth-promoting power through the accumulation of
other events.
In 1914, Theodor Boveri proposed that specific ‘‘chromosome
constitutions can be produced such that the cells that harbor it
are driven to unrestrained proliferation’’ (Boveri, 1929). Recurring
patterns of aneuploidy exist in tumors, but whether they exist
because of the frequency of occurrence of each individual
SCNA event or because they are selected due to a tumorigenic
phenotypic effect was not known. Here, we propose that the cu-
mulative phenotypic effects of gene dosage alterations of STOP
and GO genes provide the selective pressure that is responsible
for the recurrent patterns of copy number variation observed in
cancer. Our findings support the hypothesis put forward by
Boveri exactly one century ago that aneuploidy is not only a hall-
mark of cancer, but is also a driving force during the evolution of
human cancer.
EXPERIMENTAL PROCEDURES
Somatic Mutation Data Set
The data set of somatic mutations included data from The Cancer Genome
Atlas (TCGA, http://cancergenome.nih.gov/) research network and from the
Catalogue of Somatic Mutations in Cancer (COSMIC, http://cancer.sanger.
ac.uk/cancergenome/projects/cosmic/) and the data set published by Alexan-
drov et al. (2013). The data set contained 1,200,000 mutations from 8,207
tumor samples from >20 tumor types (Table S1) and will be available at
http://elledgelab.med.harvard.edu/. All data related to SCNAs were derived
from the TCGA Genome Data analysis Center at the Broad Institute (Zack
et al., 2013).
TUSON Explorer Predictions
The PolyPhen2 algorithm (Adzhubei et al., 2010) was used to predict the
functional impact of each missense mutation and to classify them as high
functional impact (HiFI) or low functional impact (LoFI). We defined the four
following classes of mutations: (1) Benign mutations: Silent + LoFI Missense;
(2) Loss of Function mutations (LOF): Nonsense and Frameshift mutations; (3)
Splicing mutations: mutations affecting splicing sites; and (4) HiFI missense
mutations. An additional parameter considered was the Entropy score, which
measures the degree of randomness of the distribution of missense
mutations.
Among 22 potential parameters, we selected the most predictive ones by
using the Lasso prediction model and three training sets of known TSGs and
OGs (from the Cancer Gene Census, Futreal et al., 2004) and putative neutral
genes. LOF/Benign, Splicing/Benign, and HiFI/Benign ratios were selected by
Lasso for the prediction of TSGs, and the HiFI/Benign ratio and the Entropy
score were selected for the prediction of OGs. TUSON predictions are based
on the calculation of a combined p value (and q value) of the selected param-
eters by using an extended version of the Liptakmethod (Tables S3A and S3B).
Based on the combined p values derived with the TUSON method, we esti-
mated the total number of predicted TSGs and OGs by using a histogram-
based method (Mosig et al., 2001).
Charm and Chrom Score and Correlation with Frequency of SCNAs
For each arm and chromosome, respectively, the Charm andChrom scores for
a certain gene set (TSGs, OGs, or essential genes) represent the density of the
genescontained in that setweightedby their predictedpotency. Thepotencyof
each gene corresponds to its rank position within its gene set list ranked by the
TUSONpvalue or by the (LOF+ 1/23HiFi)/Benign ratio for the essential genes.
For the cumulative CharmTSG-OG-Ess and ChromTSG-OG-Ess score, the scores of
OGs and essential geneswere subtracted from the scores relative to the TSGs.
The correlation analysis was performed using one-sided Pearson’s correlation
test between the Charm or Chrom score and the frequency of deletion and
amplification of each arm or chromosome across all tumors (Table S6).
Analysis of Functional Gene Sets
The STOP gene list was derived from an analysis performed using RNAi gene
enrichment ranking (RIGER) algorithm (Cheung et al., 2011) on a previously
described functional shRNA-based proliferation screen (Solimini et al., 2012;
Table S5A). An in silico list of 332 essential genes was derived by considering
the intersection between the lists of genes predicted to be housekeeping
genes and highly conserved genes (Marcotte et al., 2012; Table S5A). We
used the Fisher’s exact test to examine the significance of the association
between the presence of a gene in recurrent SCNAs (Beroukhim et al., 2010)
and its presence among a certain gene set.
For additional information, see the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and seven tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.10.011.
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